110 related articles for article (PubMed ID: 4015743)
1. [The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].
Schuster O; Haertel M; Hugemann B; Gikalov I; Schiemann O; Fenner H
Arzneimittelforschung; 1985; 35(4):760-5. PubMed ID: 4015743
[TBL] [Abstract][Full Text] [Related]
2. [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Gikalov I; Radivojevich F; Schiemann O; Fenner H
Arzneimittelforschung; 1986 Jun; 36(6):988-93. PubMed ID: 3741536
[TBL] [Abstract][Full Text] [Related]
3. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner H; Schiemann O; Gikalov I
Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
[TBL] [Abstract][Full Text] [Related]
4. The bioavailability of two commercial preparations of allopurinol tablets.
Marcus M; Tse FL; Kleinberg SI
Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):302-5. PubMed ID: 7107081
[TBL] [Abstract][Full Text] [Related]
5. [Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
Rüffer C; Zorn G; Henkel E; Mitzkat HJ
Arzneimittelforschung; 1982; 32(9):1149-52. PubMed ID: 6890841
[TBL] [Abstract][Full Text] [Related]
6. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Mertz DP; Borner K
Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
[No Abstract] [Full Text] [Related]
7. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
[TBL] [Abstract][Full Text] [Related]
8. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
Walter-Sack I; Gröbner W; Zöllner N
Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
[TBL] [Abstract][Full Text] [Related]
9. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
Berlinger WG; Park GD; Spector R
N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study of the bioavailability and the pharmacodynamic effect of five allopurinol preparations (author's transl)].
Jaeger H; Russmann D; Rasper J; Blome J
Arzneimittelforschung; 1982; 32(4):438-43. PubMed ID: 6896646
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Breithaupt B; Tittel M
Eur J Clin Pharmacol; 1982; 22(1):77-84. PubMed ID: 7094977
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.
Appelbaum SJ; Mayersohn M; Dorr RT; Perrier D
Cancer Chemother Pharmacol; 1982; 8(1):93-8. PubMed ID: 7094203
[TBL] [Abstract][Full Text] [Related]
13. Absorption and metabolism of allopurinol and oxypurinol by rat jejunum in vitro: effects on uric acid transport.
Shaw MI; Parsons DS
Clin Sci (Lond); 1984 Mar; 66(3):257-67. PubMed ID: 6692658
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of allopurinol oral and rectal dosage forms.
Chang SL; Kramer WG; Feldman S; Ballentine R; Frankel LS
Am J Hosp Pharm; 1981 Mar; 38(3):365-8. PubMed ID: 7223751
[TBL] [Abstract][Full Text] [Related]
15. A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection.
Reinders MK; Nijdam LC; van Roon EN; Movig KL; Jansen TL; van de Laar MA; Brouwers JR
J Pharm Biomed Anal; 2007 Oct; 45(2):312-7. PubMed ID: 17890037
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol, and oxypurinol during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation.
Hornbeck CL; Floyd RA; Byfield JE; Griffiths JC; Frankel S; Sharp TR
Cancer Treat Rep; 1982 Mar; 66(3):571-3. PubMed ID: 7060045
[No Abstract] [Full Text] [Related]
17. Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol.
Reiter S; Simmonds HA; Zöllner N; Braun SL; Knedel M
Clin Chim Acta; 1990 Mar; 187(3):221-34. PubMed ID: 2323062
[TBL] [Abstract][Full Text] [Related]
18. Allopurinol kinetics.
Hande K; Reed E; Chabner B
Clin Pharmacol Ther; 1978 May; 23(5):598-605. PubMed ID: 639435
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M; Sawchuk RJ
Am J Vet Res; 1997 May; 58(5):504-10. PubMed ID: 9140559
[TBL] [Abstract][Full Text] [Related]
20. [The use of allopurinol in long-term treatments for optimal effect].
Fenner H
Fortschr Med; 1980 Mar; 98(10):(373-6). PubMed ID: 7372221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
